New VETCOP study measures steroid hesitancy in canine atopy care: full analysis
Version 2
A newly published study in Veterinary Dermatology puts a name, and now a measurement tool, to a problem many clinicians likely recognize in practice: pet parent hesitation around topical steroids for dogs with atopic dermatitis. The paper introduces VETCOP, a veterinary adaptation of the human TOPICOP questionnaire, and reports that topical corticosteroid phobia was common among surveyed pet parents in China and Singapore. The authors argue that this fear can become a practical barrier to adherence and, in turn, to disease control. (researchgate.net)
That matters because canine atopic dermatitis is not a short, simple treatment course. It is a chronic, relapsing inflammatory skin disease that affects a meaningful share of dogs, with Cornell noting prevalence estimates around 10% to 15% of the canine population. Clinical management typically requires a multimodal plan, repeated reassessment, and sustained pet parent participation over time. Merck Veterinary Manual also emphasizes that client education is important because the disease is lifelong and requires ongoing management and regular progress checks. (vet.cornell.edu)
Against that backdrop, the VETCOP study is notable less because it changes treatment standards than because it tries to quantify a behavioral obstacle to using an established therapy. According to the article record, 363 respondents were enrolled, and the survey instrument was built by adapting the validated human TOPICOP scale for veterinary use, with four additional questions. The concept is familiar from human dermatology, where earlier research found that fear of topical corticosteroids was widespread and associated with a need for reassurance, concerns about systemic absorption, prior adverse experiences, inconsistent instructions, and poor adherence. The veterinary study appears to bring that framework into canine dermatology practice. (researchgate.net)
The study also lands in an area where the profession already has fairly clear therapeutic guidance. ICADA’s treatment guidelines state that topical glucocorticoids are effective for acute flares of canine atopic dermatitis, especially for localized lesions and short durations, but they also caution that long-term daily application at the same sites can lead to skin atrophy. Additional veterinary studies have shown benefit for hydrocortisone aceponate spray, including work suggesting it can help maintain control as systemic therapy is tapered, and earlier research finding efficacy comparable to oral ciclosporin in some settings. In other words, these drugs are neither trivial nor fringe: they are useful tools that require appropriate case selection, dosing, and communication. (bmcvetres.biomedcentral.com)
While I did not find outside commentary specifically reacting to this VETCOP paper, the broader literature supports the authors’ premise that adherence is a weak point in atopic dermatitis care. Human dermatology research has long tied steroid fear to underuse and treatment failure, and veterinary reference sources similarly frame atopic dermatitis management as a partnership that depends on pet parent understanding and follow-through. That gives the VETCOP work practical relevance even before broader validation studies appear: it offers a structured way to identify which concerns are driving reluctance in the exam room. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this study is a reminder that resistance to treatment may not always be about cost, convenience, or lack of efficacy. It may stem from specific beliefs about safety, absorption, duration of use, or prior bad experiences, all of which can be addressed more effectively if they are surfaced early. In busy primary care and dermatology settings, a tool like VETCOP could help clinicians distinguish between a pet parent who needs more reassurance, one who needs clearer application instructions, and one who may be better served by a different therapeutic plan. That has implications not just for adherence, but for case satisfaction, flare frequency, and whether a dog is escalated unnecessarily to more complex or costly therapies. (researchgate.net)
What to watch: The next meaningful step will be external validation, ideally in additional geographies and practice types, along with studies that connect VETCOP scores to measurable adherence and clinical outcomes. It would also be useful to see whether the tool can guide targeted communication interventions, such as standardized counseling or written steroid-use protocols, and whether those changes improve control of canine atopic dermatitis over time. (researchgate.net)